Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

April 8, 2025

Study Completion Date

May 31, 2029

Conditions
Osteoarthritis, KneeOsteo Arthritis KneeKnee Osteoarthritis
Interventions
GENETIC

GNSC-001

intra-articular injection

DRUG

transient immune-modulation

oral

DRUG

transient immune-modulation

intra-articular injection

DRUG

Placebo

intra-articular injection

Trial Locations (9)

16635

Altoona Center for Clinical Research, Duncansville

28557

West Clinical Research, Morehead City

32159

Premier Medical Associates, The Villages

33166

South Florida Research, Miami Springs

33173

Well Pharma Medical Research, Miami

36608

Alliance for Medical Research Mobile, Mobile

64114

Alliance for Multispecialty Research Kansas City, Kansas City

91942

Biosolutions Clinical Research Center, La Mesa

92037

UC San Diego, San Diego

Sponsors
All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Genascence Corporation

INDUSTRY

NCT05835895 - Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis | Biotech Hunter | Biotech Hunter